765962-22-9

Upstream product

• 55-51-6 N,N-bis(2-chloro-ethyl)-benzenemethanamine 
• 105-53-3 diethyl malonate 
• 10429-82-0 N-benzyl-2-chloro-N-(2-chloroethyl)ethanamine hydrochloride 
• 101-32-6 N-benzyl-diethanolamine 

Downstream Products

• 374794-84-0 tert-butyl 4,4-bis(hydroxymethyl)piperidine-1-carboxylate 
• 240401-27-8 2-oxa-7-azaspiro[3.5]nonane-7-carboxylic acid tert-butyl ester 
• 1093214-66-4 1-{4-[5-(4-trifluoromethylphenyl)-1,2,4-oxadiazol-3-yl]benzyl}piperidine-4,4-dicarboxylic acid diethyl ester 
• 1093212-39-5 1-{4-[5-(4-trifluoromethylphenyl)-1,2,4-oxadiazol-3-yl]benzyl}piperidine-4,4-dicarboxylic acid 
• 1093214-67-5 (Z)-1-{4-[5-(furan-2-yl)methoxyiminomethyl-1,2,4-oxadiazol-3-yl]benzyl}piperidine-4,4-dicarboxylic acid diethyl ester 

Relevant academic research and scientific papers

SUBSTITUTED OXAZOLIDINONES FOR THE TREATMENT OF MAMMALIAN INFECTIONS

Present invention relates to novel compound of formula (I), their enantiomers, their diastereomers, their pharmaceutically accepted salts, or pro-drugs thereof, which are useful for the treatment of bacterial infection.

NOVEL DICARBOXYLIC ACID DERIVATIVES AS S1P1 RECEPTOR AGONISTS

The present invention relates to new compounds of formula (I) possessing agonistic activity at sphingosine-1 -phosphate (S1 P) receptors, their process of preparation and their use as immunosuppressive agents. The invention is also directed to pharmaceutical compositions containing these compounds and use of these compounds for treatment/prevention of immune mediated diseases and conditions or inflammatory diseases and conditions.